99mTc HYNIC-TOC imaging and 177Lu DOTA-octreotate treatment in non-iodine-concentrating dedifferentiated thyroid carcinoma metastases: an unusual alternative diagnosis
dc.contributor.author | Basu, Sandip | |
dc.contributor.author | Joshi, A. | |
dc.date.accessioned | 2015-07-29T10:16:03Z | |
dc.date.available | 2015-07-29T10:16:03Z | |
dc.date.issued | 2014 | |
dc.description.division | RMC | en |
dc.format.extent | 4038 bytes | |
dc.format.mimetype | text/html | |
dc.identifier.source | Clinical Nuclear Medicine, 2014. Vol. 39 (7): pp. 632-634 | en |
dc.identifier.uri | http://hdl.handle.net/123456789/11441 | |
dc.language.iso | en | en |
dc.subject | papillary thyroid carcinoma | en |
dc.subject | neuroendocrine tumor | en |
dc.subject | peptide receptor radionuclide therapy | en |
dc.subject | 177Lu DOTA-octreotate therapy | en |
dc.subject | 99mTc HYNIC-TOC | en |
dc.subject | somatostatin receptor scintigraphy | en |
dc.title | 99mTc HYNIC-TOC imaging and 177Lu DOTA-octreotate treatment in non-iodine-concentrating dedifferentiated thyroid carcinoma metastases: an unusual alternative diagnosis | en |
dc.type | Article | en |